01
Evidence Strategy & Market Access Planning
U.S. payer evidence strategy; HEOR evidence gap assessment; launch and access planning; competitive evidence landscape analysis; IRA/CMS policy impact assessment.
Evidence that shapes access decisions. Fit-for-purpose evidence designed to meet the needs of formulary, coverage, and pricing decisions.
Direct access to national administrative claims databases.
U.S. payer evidence strategy; HEOR evidence gap assessment; launch and access planning; competitive evidence landscape analysis; IRA/CMS policy impact assessment.
Leveraging direct access to nationally representative claims databases. Burden-of-illness studies; treatment patterns and adherence analyses; healthcare resource utilization and cost studies; comparative effectiveness research; AI-driven analytics.
Budget impact models (BIMs); cost-effectiveness and cost-utility analyses (CEA/CUA); cost-minimization models; Markov and partitioned survival models; novel value frameworks (GRACE, HYT). Interactive payer-facing Excel models.
Craft clear, impactful payer materials. We prepare AMCP dossiers, global value dossiers, and concise value stories. Our team also develops objection handler toolkits and publication strategies.
Design pricing and contracting plans that work in practice. We simulate pricing under alternative payer models (value-based pricing, rebate structures) at local and federal levels, craft outcomes-based contracts, and address policy and equity considerations using next-gen frameworks like GRACE and HYT.